Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Asiatic Laboratories's cash to debt ratio for the quarter that ended in . 20 was 0.00.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Asiatic Laboratoriescouldn't pay off its debt using the cash in hand for the quarter that ended in . 20.
The historical rank and industry rank for Asiatic Laboratories's Cash-to-Debt or its related term are showing as below:
DHA:ASIATICLAB's Cash-to-Debt is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.995 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Asiatic Laboratories Cash-to-Debt Related Terms
Asiatic Laboratories Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Asiatic Laboratories's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Asiatic Laboratories Cash-to-Debt Chart
Asiatic Laboratories Annual Data
Trend
Cash-to-Debt
Asiatic Laboratories Semi-Annual Data
Cash-to-Debt
DHA:ASIATICLAB vs ZTS, UTHR, VTRS: Cash-to-Debt Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Asiatic Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asiatic Laboratories Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Asiatic Laboratories's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Asiatic Laboratories's Cash-to-Debt falls into.
Asiatic Laboratories's Cash to Debt Ratio for the fiscal year that ended in . 20 is calculated as:
Do not have enough data to calculate Cash to Debt ratio.
Asiatic Laboratories's Cash to Debt Ratio for the quarter that ended in . 20 is calculated as:
Do not have enough data to calculate Cash to Debt ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asiatic Laboratories (DHA:ASIATICLAB) has a Cash-to-Debt of 0.00 as of . 20. According to the industry distribution chart, Asiatic Laboratories ranks #999999 out of 986 companies in the Drug Manufacturers industry.
Is Asiatic Laboratories' Cash-to-Debt too high?
Asiatic Laboratories' current Cash-to-Debt is 0.00. Based on the distribution chart, Asiatic Laboratories ranks #999999 out of 986 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Asiatic Laboratories has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Asiatic Laboratories' Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Asiatic Laboratories ranks #999999 out of 986 companies for Cash-to-Debt. This places Asiatic Laboratories in the lower half of its industry. The industry median Cash-to-Debt is 1.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 1.00, based on 986 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 1.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asiatic Laboratories's current Cash-to-Debt is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asiatic Laboratories stock overvalued right now?
Asiatic Laboratories (DHA:ASIATICLAB) has a current Cash-to-Debt of 0.00. The current Cash-to-Debt is 0.00. Asiatic Laboratories' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Asiatic Laboratories (DHA:ASIATICLAB), the current Cash-to-Debt is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asiatic Laboratories Ltd is engaged in manufacturing and marketing of a wide range of the rapeutical medicines pharmaceutical products in the categories of Biological, Non-Biological & Sterile Pharmaceutical dosage. It has 80 generic molecules comprising therapeutic classes like antibiotics, antihistamines, bronchodilators, vitamins-minerals, antiulcerants, laxatives, gastroprokinetics, antihematinic, anthelmentics, CNS drugs, respiratory drugs, NSAIDs, dermatological preparations and sterile ophthalmic preparations.
32GF Score
Get the complete analysis for DHA:ASIATICLAB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ASIATICLAB has been successfully added to your 
